Less Ads, More Data, More Tools Register for FREE

Pin to quick picksALM.L Regulatory News (ALM)

  • There is currently no data for ALM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of New Non-Executive Chairman

28 Apr 2015 07:00

RNS Number : 4543L
Allied Minds PLC
28 April 2015
 



 

 

28 APRIL 2015

 

Allied Minds plc (the "Company")

 

Appointment of New Non-Executive Chairman

 

Allied Minds plc, an innovative U.S.-focused science and technology development and commercialisation company, today announces that Mr. Peter Dolan will be appointed to the role of Non-Executive Chairman of the board of directors of the Company ("Board"), with effect from the conclusion of the Company's Annual General Meeting on 28 May 2015. Mr. Dolan will replace the current Executive Chairman, Mr. Mark Pritchard, who will remain on the Board in an executive capacity in the short term but intends to step down from the Board later in the year, although he is expected to continue to be actively engaged with the Company. Mr. Pritchard founded Allied Minds in 2004 and has been directly involved in its strategic direction and growth since inception, most recently taking the role of Chairman of the Board as the Company listed on the Main Market of the London Stock Exchange in June 2014. The appointment of Mr. Dolan, an independent non-executive director, will further the Company's compliance with best practices of the UK Corporate Governance Code.

 

Mr Dolan was appointed to the Board of Allied Minds plc in May 2014. Mr Dolan is currently the Chairman of the Board of Trustees of Tufts University. Mr. Dolan has more than 30 years of operating experience, including 18 years at Bristol-Myers Squibb, where he served as Chairman and CEO. He subsequently served as Chairman and CEO of Gemin X, a venture capital backed oncology company that was sold to Cephalon, a U.S. based biopharmaceutical company, in 2011. Additionally, among several other appointments, he has served on the board of directors of the American Express Company and was Chairman of the Pharmaceutical Research and Manufacturers of America.

 

Chris Silva, CEO commented:

"On behalf of the Board and employees of Allied Minds, I wish to thank Mark for his important contributions since the Company's inception, and for his leadership as Chairman. During his tenure, Mark's vision and dedication to creating a new paradigm for early-stage investing has created tremendous benefit for all stakeholders - from the scientists and engineers who have seen their inventions transformed into commercial products, to the investors who have shared in the creation of significant value. I am grateful that Mark will continue as an active member of the senior leadership team.

"I am also delighted that Peter has agreed to succeed him. Peter's deep experience in leading complex organisations and boards, and working closely with stakeholders, will be a powerful asset for the Company as it continues to grow. I look forward to his contributions and guidance as we seek to achieve the Company's long-term strategic and business objectives."

Peter Dolan said:

 

"I am delighted to take on the role of Chairman of the Board for Allied Minds. We are fortunate at Allied Minds to have a diverse, dynamic, and dedicated group of experienced professionals who are committed to the Company's vision of transforming U.S. invention into innovative products and companies. The responsibilities of Chairman are substantial yet exhilarating, and I look forward to helping Allied Minds continue to develop its partnerships, early-stage technology and new company investment. I would like to thank Mark for building Allied Minds into a leader in technology commercialisation, and I am excited to take a more active role at the Company as it embarks on its next phase of growth." 

 

For more information, please contact:

Allied Minds plc www.alliedminds.com

Mark Pritchard, Executive Chairman +1 617 419 1800

Chris Silva, Chief Executive Officer +1 617 419 1800

FTI Consulting

Ben Atwell, Matthew Cole +44 (0) 20 3727 1000

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOASEFFMWFISEFL
Date   Source Headline
7th Dec 201812:02 pmRNSPrice Monitoring Extension
6th Dec 201812:02 pmRNSPrice Monitoring Extension
4th Dec 20187:00 amRNSHawkEye 360 successful pathfinder satellite launch
12th Nov 20187:00 amRNSSpin Memory series B and commercial partnerships
9th Nov 20185:09 pmRNSBlocklisting Six Monthly Return
9th Nov 20185:05 pmRNSBlocklisting Six Monthly Return
27th Sep 20187:00 amRNSHalf-year Report
24th Sep 20187:00 amRNSSTT announces appointment of Chairman
18th Sep 20187:00 amRNSAllied Minds forms QuayChain subsidiary
10th Sep 20187:00 amRNSFederated Wireless update
10th Sep 20187:00 amRNSHawkEye 360 completes second Series A-3 funding
10th Sep 20187:00 amRNSBridgeSat raises $10.0 million Series B financing
15th Aug 20184:35 pmRNSPrice Monitoring Extension
13th Aug 20187:03 amRNSNotice of Results
13th Aug 20187:00 amRNSHawkEye 360 raises $9.6m in Series A-3 financing
11th Jul 20184:35 pmRNSPrice Monitoring Extension
11th Jul 20187:00 amRNSPrecision Biopsy appoints Chief Operating Officer
2nd Jul 20183:15 pmRNSTotal Voting Rights
26th Jun 20185:17 pmRNSDirector/PDMR Shareholding
19th Jun 20184:54 pmRNSDirector/PDMR Shareholding
19th Jun 20184:48 pmRNSDirector/PDMR Shareholding
19th Jun 20184:38 pmRNSDirector/PDMR Shareholding
12th Jun 201811:12 amRNSDirector/PDMR Shareholding
31st May 20187:00 amRNSDirectorate Change
23rd May 20183:30 pmRNSResult of AGM
23rd May 20187:00 amRNSTrading Statement
16th May 20181:25 pmRNSDirector/PDMR Shareholding
16th May 201811:24 amRNSDirector/PDMR Shareholding
16th May 201810:51 amRNSDirector/PDMR Shareholding
16th May 20187:00 amRNSFederated Wireless Update
11th May 20189:38 amRNSBlocklisting Six Monthly Return
11th May 20189:31 amRNSBlocklisting Six Monthly Return
1st May 20183:09 pmRNSHolding(s) in Company
9th Apr 20188:25 amRNSAllied Minds leads funding round at TableUp
9th Apr 20188:25 amRNSAllied Minds leads Orbital Sidekick funding round
6th Apr 20187:00 amRNSNotice of AGM and Annual Report
3rd Apr 201811:26 amRNSTotal Voting Rights
22nd Mar 20187:01 amRNSDirectorate Change
22nd Mar 20187:00 amRNSAnnual Financial Report
8th Mar 20187:00 amRNSNotice of Results
1st Mar 20182:17 pmRNSTotal Voting Rights
1st Feb 201810:20 amRNSTotal Voting Rights
22nd Jan 20183:25 pmRNSDirector/PDMR Shareholding
22nd Jan 20183:22 pmRNSDirector/PDMR Shareholding
18th Jan 20187:00 amRNSCapital Markets Day Materials
17th Jan 20187:00 amRNSAllied Minds: Sale of Percipient Networks
11th Jan 20187:00 amRNSSTT's $22.8m convertible bridge facility
19th Dec 201712:02 pmRNSPrice Monitoring Extension
18th Dec 20177:00 amRNSSciFluor: results of phase 1/2 study of SF0166
30th Nov 201712:12 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.